Overview

* Entrada Therapeutics ( TRDA ) Q2 net loss of $43.1 mln vs. net income last yr

* Collaboration revenue drops sharply to $2 mln from $94.7 mln last yr

* Cash position at $354 mln, sufficient to fund operations into Q2 2027

Outlook

* Company expects cash runway to last into Q2 2027

* Entrada anticipates reporting ELEVATE-44-201 data in H1 2026

* Company plans regulatory submission for ENTR-601-50 in Q4 2025

* Entrada expects ELEVATE-45-201 data readout in mid-2026

Result Drivers

* CLINICAL TRIAL PROGRESS - First patient dosed in ELEVATE-44-201 and multiple sites activated for ELEVATE-45-201

* R&D EXPENSES - Increased costs due to advancement of Duchenne muscular dystrophy programs

* COLLABORATION REVENUE DROP - Sharp decline in revenue attributed to completion of Vertex collaboration activities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $1.95

Collabor mln

ation

Revenue

Q2 EPS -$1.04

Q2 Net -$43.10

Income mln

Q2 -$46.85

Income mln

From

Operatio

ns

Q2 $48.80

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Entrada Therapeutics Inc ( TRDA ) is $20.50, about 71.6% above its August 5 closing price of $5.83

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)